Previous Close | 12.26 |
Open | 12.01 |
Bid | 11.91 x 800 |
Ask | 12.00 x 800 |
Day's Range | 11.63 - 12.33 |
52 Week Range | 4.30 - 17.89 |
Volume | |
Avg. Volume | 212,832 |
Market Cap | 618.079M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.11 |
Earnings Date | Nov 02, 2022 - Nov 07, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 24.83 |
Subscribe to Yahoo Finance Plus to view Fair Value for DYN
- FORCE™ Platform Achieves Enhanced Exon Skipping and Prolonged Dystrophin Restoration in Duchenne in vivo mdx Model - WALTHAM, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the publication of Duchenne muscular dystrophy (DMD) preclinical data in a “Breakthrough Article” in Nucleic Acids Resear
- Initiation of Patient Dosing in Multiple Ascending Dose Clinical Trials for DYNE-251 in DMD and DYNE-101 in DM1 On Track for Mid-2022 - WALTHAM, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the second quarter of 2022 and business highlights. “We are executing on our glob
DINO, DYN, and DLNG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 18, 2022.